Skip to content
OpenCapital
Get started

Biohaven BHVN Issuance of stock under employee stock plans

Issuance of stock under employee stock plans at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
——

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's issuance of stock under employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's issuance of stock under employee stock plans?
Biohaven (BHVN) reported issuance of stock under employee stock plans of $132K in Q1 2026.
How has Biohaven's issuance of stock under employee stock plans changed year-over-year?
Biohaven's issuance of stock under employee stock plans decreased by 64.2% year-over-year, from $369K to $132K.
What is the long-term trend for Biohaven's issuance of stock under employee stock plans?
Over 3 years (2021 to 2024), Biohaven's issuance of stock under employee stock plans has grown at a 207.6% compound annual growth rate (CAGR), from $395K to $11.5M.